SEC Form 4 · accession 0001179110-17-002279
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy A Simonian
Officer — President & CEO · Director
Period of report
Feb 10, 2017
Accepted (ET)
Feb 13, 2017 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.90 | Feb 10, 2017 | A | 175,000 | A | — | Feb 9, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1This option becomes exercisable as to 25% of the shares underlying the award on February 10, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.